D0958 | idarubicin hydrochloride
L
L01DB06 Idarubicin
[L01DB] Anthracyclines and related substances
[L01D] CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
[L01] ANTINEOPLASTIC AGENTS
[L] Antineoplastic and immunomodulating agents
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 6.83±1.46 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | human | HepG2 | MMP assay | Negative | IC50 | 163 | ||
| MEMBRANE POTENTIAL | 27.02±10.70 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 124 companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral] H341 (25%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] H351 (98.39%): Suspected of causing cancer [Warning Carcinogenicity] H360 (99.19%): May damage fertility or the unborn child [Danger Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P264, P270, P281, P301+P310, P308+P313, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | oral | 13980ug/kg (13.98mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| mouse | LD50 | subcutaneous | 4690ug/kg (4.69mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| rat | LD50 | intravenous | 3080ug/kg (3.08mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| rat | LD50 | oral | 5430ug/kg (5.43mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| mouse | LD50 | intravenous | 4100ug/kg (4.1mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| rat | LD50 | subcutaneous | 2930ug/kg (2.93mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| dog | LD | intravenous | > 500ug/kg (0.5mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995. | |
| mouse | LDLo | intraperitoneal | 700ug/kg (0.7mg/kg) | Cancer Treatment Reports. Vol. 60, Pg. 829, 1976. | |
| (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, hydrochloride | (7S,9S)-9-acetyl-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride | (7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride |
| (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; | (7S-cis)-9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride | 33820-EP2275420A1 |
| 33820-EP2295055A2 | 33820-EP2295416A2 | 33820-EP2298748A2 |
| 33820-EP2298764A1 | 33820-EP2298765A1 | 33820-EP2298768A1 |
| 33820-EP2305642A2 | 33820-EP2311453A1 | 4-Demethoxydaunorubicin hydrochloride |
| 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis)- | 57852-57-0 | 5VV3MDU5IE |
| 852I570 | AC-5255 | AKOS025402118 |
| API0002971 | C26H27NO9.HCl | CAS-57852-57-0 |
| CCG-100886 | CHEBI:31686 | CHEMBL1200976 |
| CPD000466355 | CS-1061 | D01747 |
| DMDR | DSSTox_CID_27775 | DSSTox_GSID_47797 |
| DSSTox_RID_82550 | DTXSID0047797 | Daunomycin, 4-demethoxy-, hydrochloride |
| EINECS 260-990-7 | EX-A1148 | HY-17381 |
| IMI 30 | IMI-30 | Idamycin |
| Idamycin (TN) | Idamycin PFS | Idarubicin (hydrochloride) |
| Idarubicin Hcl | Idarubicin hydrochlorid | Idarubicin hydrochloride (JP17/USP) |
| Idarubicin hydrochloride PFS | Idarubicin hydrochloride [USAN:USP:INN] | JVHPTYWUBOQMBP-RVFAQHLVSA-N |
| KSC-230-185-1 | KUC110342C | MFCD00866457 |
| MLS000759470 | MLS001401448 | NC00136 |
| NCGC00093976-03 | NCGC00093976-08 | NSC 256439 |
| NSC-256439 | Q-101407 | Q27262943 |
| SAM001246676 | SC-25438 | SCHEMBL4838 |
| SMR000466355 | SR-01000075934 | SR-01000075934-5 |
| Tox21_111236 | Tox21_111236_1 | UNII-5VV3MDU5IE |
| W-5198 | Zavedos | idarubicin hydrochloride |
| s1228 |